The purpose of this paper was to compare results of next generation sequencing (NGS), Sanger sequencing and a real-time PCR genotyping assay obtained from formalin-fixed paraffin-embedded (FFPE) colorectal carcinoma (CRC) specimens.
Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.
Gao J, Wu H, Wang L, Zhang H, Duan H, Lu J, Liang Z
Purpose
Conclusion
NGS and Sanger sequencing genotyping results were 100% concordant for KRAS exon 2, 3, and 4 and NRAS exon 3, but NGS allowed for detection of mutations with frequencies as low as 1% while Sanger sequencing was only reliable for mutations with frequencies of more than 10%. One mutation of 13 KRAS exons 2 mutations was missed by real-time PCR genotyping, but it was not targeted in the Real-time PCR assay.
Studies (1)
Purpose
This study compared results of NGS, Sanger sequencing and a real-time PCR genotyping assay obtained from FFPE colorectal carcinoma (CRC) blocks. Archived FFPE blocks from 51 cases of colorectal carcinoma were selected. Tumor cells were enriched by macrodissection of up to ten unstained 5 mm sections to obtain 60-95% tumor content. DNA was extracted with the QIAamp DNA Mini Kit and quantified using the Qubit assay. Libraries for Ion Torrent PGM sequencing were prepared using the AmpliSeq Cancer Hotspot Panel v2. Real-time PCR assays were conducted using the Therascreen KRAS mutation kit.
Summary of Findings
Of 51 specimens, 13 were identified by NGS to contain a KRAS exon 2 mutation at frequencies of 22.2-59.1%. Genotyping results were 100% concordant with those from Sanger sequencing. One mutation was missed by real-time PCR genotyping, but it was a mutation not targeted by the real-time PCR platform used. Importantly, using a diluted FFPE cancer cell line it was shown that NGS could detect KRAS mutations at frequencies as low as 1% while peaks in Sanger sequencing were hard to distinguish from background at levels below 10%. NGS was also able to detect RAS mutations in KRAS exons 3 and 4 and NRAS exon 3, all of which were confirmed by Sanger sequencing. However, one mutation with a frequency of 14.1% was difficult to observe by Sanger sequencing. NGS also allowed for the identification of additional mutations in other colorectal carcinoma related genes.
Biospecimens
TissueColorectalPreservation Types
FormalinDiagnoses
NeoplasticCarcinomaPlatforms
DNANext generation sequencingDNADNA sequencingDNAReal-time qPCRPre-analytical Factors
Classification Pre-Analytical Factor Value(s) DNA sequencing Specific Targeted nucleic acid KRAS exon 2KRAS exon 3KRAS exon 4NRAS exon 3DNA sequencing Specific Technology platform Ion Torrent PGM next-generation sequencingReal-time-PCR using TherascreenSanger sequencing